- Home
- IRON vs VERA Comparison
IRON vs VERA Comparison
Compare IRON & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- VERA
- Stock Information
- Founded
- IRON 2017
- VERA 2016
- Country
- IRON United States
- VERA United States
- Employees
- IRON N/A
- VERA N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- IRON Health Care
- VERA Health Care
- Exchange
- IRON Nasdaq
- VERA Nasdaq
- Market Cap
- IRON 1.4B
- VERA 1.6B
- IPO Year
- IRON N/A
- VERA 2021
- Fundamental
- Price
- IRON $46.68
- VERA $18.95
- Analyst Decision
- IRON Strong Buy
- VERA Buy
- Analyst Count
- IRON 9
- VERA 8
- Target Price
- IRON $93.89
- VERA $64.00
- AVG Volume (30 Days)
- IRON 354.8K
- VERA 1.3M
- Earning Date
- IRON 05-07-2025
- VERA 05-06-2025
- Dividend Yield
- IRON N/A
- VERA N/A
- EPS Growth
- IRON N/A
- VERA N/A
- EPS
- IRON N/A
- VERA N/A
- Revenue
- IRON N/A
- VERA N/A
- Revenue This Year
- IRON N/A
- VERA N/A
- Revenue Next Year
- IRON N/A
- VERA N/A
- P/E Ratio
- IRON N/A
- VERA N/A
- Revenue Growth
- IRON N/A
- VERA N/A
- 52 Week Low
- IRON $30.82
- VERA $18.53
- 52 Week High
- IRON $68.73
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- IRON 49.90
- VERA 35.84
- Support Level
- IRON $44.85
- VERA $18.76
- Resistance Level
- IRON $47.36
- VERA $20.21
- Average True Range (ATR)
- IRON 2.23
- VERA 0.90
- MACD
- IRON -0.12
- VERA -0.16
- Stochastic Oscillator
- IRON 37.58
- VERA 4.46
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.